By targeting GATA3 and PTEN, miR-10b alters the balance between pathogenic and regulatory T cells, e.g., Th17 versus Treg cells and Th1 versus Th2 cells, resulting in an imbalance in CD4+ T cell polarization in RA patients, followed by a high expression of cytokines, mainly IFN and IL-17A. Here, CD4 is linked to rheumatoid arthritis.